Date
14 November 2026
Millions still face barriers to essential medicines despite company efforts
The Index finds that access plans now cover 69% of medicines in late-stage development, more than three times the share in 2018. Ahabwe sets this growth in planning against persistent barriers to affordability, availability and distribution. Marking 20 years of the Index, the 2026 assessment also puts greater emphasis on implementation and measurable results, distinguishing company commitments from progress.Â
Cancer shows how uneven the plans remain: strategies have been developed for 74% of assessed cancer products in lower-middle-income countries, compared with 19% in low-income countries. For diabetes, access to newer treatments remains limited in many low-income markets, while insulin is still expensive or difficult for many patients to obtain.Â
The article also reports that six companies run inclusive business programmes across multiple countries, collectively covering all 113 countries assessed. However, limited product- and country-level information makes their actual impact difficult to measure. Claudia MartÃnez, the Foundation’s Director of Research, says positive developments in medicine approvals, research and licensing agreements remain concentrated among a small number of companies and disease areas. She calls on more manufacturers to adopt successful approaches.Â